These findings suggested that blocking MET activation is sufficient to attenuate the enhanced metastatic potential induced by VEGF inhibition, and simultaneous blocking MET and VEGF signaling might provide more therapeutic benefit for HCC patients. Here, VEGFA is linked to hepatocellular carcinoma.